Every clinic in the country is being asked about polynucleotides. The product reps have done their job. The Instagram clinics have done theirs. The clients have read enough that they are walking in asking about salmon DNA by name.
The practitioners I speak to are split into three groups. Some are quietly using polynucleotides on most consultations and selling them confidently. Some are openly sceptical and refusing to introduce them at all. The largest group, and the reason this post exists, are the practitioners who feel pressure to offer the treatment but are not sure what the evidence actually says, what the regulator thinks, or how to price and present it without making claims that will sit badly under scrutiny.
This post is the read-out I give to practitioners inside the Skin Specialist Programme when this question comes up. It is the evidence summary, the regulatory frame, and the consultation language I would use if a client walked into Visage Aesthetics tomorrow and asked.
What polynucleotides actually are
Polynucleotides, in the aesthetic context, are short DNA fragments most commonly derived from purified salmon trout sperm. The product on the UK market is supplied as a sterile injectable gel of polynucleotide chains, sometimes alone, sometimes in combination with hyaluronic acid carriers.
The proposed mechanism, drawing on the polydeoxyribonucleotide (PDRN) literature that predates the aesthetic application, sits across three pathways. The DNA fragments are thought to act on adenosine A2A receptors, modulate inflammatory cytokines, and supply nucleotide precursors that fibroblasts can use to synthesise extracellular matrix proteins, principally collagen type I, type III, and elastin.
That is the mechanism story. It is also where the marketing tends to overshoot the data, so it is worth being precise about what the published clinical literature does and does not support.
What the evidence supports
The PDRN evidence base predates the aesthetic boom by twenty years. Most of the higher-quality studies come from wound-healing, ophthalmology, and orthopaedic indications, and demonstrate genuine bioactivity. That foundation is sometimes used as a hand-wave to support cosmetic claims, but the wound-healing evidence is not interchangeable with rejuvenation evidence and should not be cited as if it is.
The aesthetic-specific evidence is younger, smaller, and predominantly Korean. Within that body of work, the more credible signals are:
- Skin quality improvements, in the form of measured hydration gains, modest improvement in fine periorbital lines, and improved skin texture on validated photographic scales. Effect sizes are modest and the comparator arms are not always strong.
- Periorbital and infra-orbital improvement in selected patient cohorts, with most published studies running three to six sessions at two-week to four-week intervals.
- Tolerability. The safety profile in published series is reassuring for a properly administered injectable, with the usual injection-site events (bruising, tenderness, transient swelling) and a low rate of serious adverse events.
That is the honest read of the supporting evidence as it sits in 2026. It is not nothing. It is also not the transformative biologic regenerative effect the marketing collateral often implies.
What the evidence does not support
Several claims travel through the trade press and the social channels that the published literature does not currently support. If you are quoting any of the following to a client, you are stepping outside the evidence and, depending how you phrase it, possibly outside the Advertising Standards Authority code:
- Hair loss reversal. The PDRN scalp-injection evidence is at the level of small, often uncontrolled case series. Marketing it as a treatment for androgenetic alopecia or female pattern hair loss is not supported by the published trial evidence.
- Breast tissue rejuvenation. Off-licence and clinically aggressive. Stay away.
- Scar revision as a stand-alone modality. The evidence for polynucleotides as adjunctive to other modalities is more interesting than the evidence for them as a stand-alone scar treatment.
- Replacement of hyaluronic acid filler. Polynucleotides are not volumising. They do not replace structural filler. The two have different indications and should be discussed and priced differently.
- Anti-ageing as a category claim. The ASA has been steadily tightening cosmetic injectable advertising and broad anti-ageing claims attract scrutiny.
You can use polynucleotides confidently inside the indications the evidence supports. You cannot stretch them to indications the evidence does not, and the regulator will increasingly push back on practitioners who try.
The UK regulatory position
This is the part most practitioners under-research. Polynucleotide products in the UK occupy an uncomfortable space across three regulators.
MHRA. The classification of an injectable polynucleotide product turns on its presentation, claims, and intended use. An injectable that is presented or marketed for a therapeutic effect (treating a condition, restoring a physiological function) crosses into medicinal product territory. The MHRA borderline products guidance is the document to read if you want to understand how this is assessed. Some polynucleotide products on the UK market are CE/UKCA marked as medical devices. Others, depending on their claims, may be considered medicines. The classification is not always settled and is worth checking on the specific product you are using.
JCCP. The Joint Council position is that practitioners offering injectable polynucleotides should hold the appropriate clinical training, indemnity, and prescribing pathway, and that practice should sit within statutorily regulated supervision. If you are not clear which framework your supply, prescribing, and administration sit under, that is the gap to close before your next polynucleotide consultation.
ASA. The Advertising Standards Authority has ruled repeatedly against cosmetic injectable advertising that makes unsupported efficacy claims, conflates non-prescription and prescription products, or implies medical benefit without evidence. Polynucleotide marketing copy that makes regenerative or therapeutic claims is the highest-risk category here.
In short: do not assume polynucleotides sit in a permissive regulatory grey zone because they are new. They sit in an active enforcement zone because they are new.
The consultation script
When a client asks me about polynucleotides, my consultation runs along these lines, and I teach the same approach inside the Skin Specialist Programme.
I describe what they are, in plain language, including their origin. Some clients have a religious or dietary objection to a fish-derived product and they need that information up front, not after the consent form is signed.
I describe what the evidence supports. Skin-quality improvement, modest measurable change, three to six sessions, full effect at three months from the final treatment. I do not describe them as transformative, regenerative in a category sense, or a replacement for other modalities.
I describe what the evidence does not support, in language the client can understand, and I tell her honestly which of her concerns this product is and is not the right answer to. If her primary concern is volume loss, polynucleotides are not the right primary intervention.
I price them honestly. Multi-session protocols at this price point need to be pre-quoted and consented in writing. The client who finds out at session three that the full course will cost more than her original quote will not return.
I document the consent, the indication, the session number, and the photographs. If the regulator does ever ask, the practitioners with clean records and honest documentation will sit comfortably.
Why this matters for your practice
Polynucleotides are a useful addition to the toolkit for the right indications. They are also the ingredient most likely to land a UK practitioner in front of the JCCP or the ASA in the next eighteen months, because the marketing has run faster than the evidence and the regulators are catching up.
The injectors I have watched do well with polynucleotides are the ones who learned the actual evidence base, kept their claims tight, set realistic client expectations, and built their pricing around what the treatment can honestly deliver. The injectors who are about to have a difficult year are the ones who absorbed the rep deck and the social posts and assumed the rest of the framework was sorted.
Be the first group.
Continue your reading
The full evidence summary, the consultation script, the pricing model, and the consent template I use in clinic sit inside the Skin Specialist Programme. For the regulatory side specifically, including how the MHRA borderline rules apply to your specific product list and how to keep your advertising ASA-safe, the RAG Pathway is the four-week deep dive. The eight UK regulators we teach against, with the specific clauses each enforces, are at /standards.
Bernadette Tobin is a Registered Nurse and Independent Nurse Prescriber with an MSc in Advanced Practice (Level 7). She is the founder of Aesthetics Unlocked and a 2026 Educator of the Year Nominee at the Beauty & Aesthetics Awards. She runs Visage Aesthetics in Essex, named Best Non-Surgical Aesthetics Clinic 2026 by the Health, Beauty & Wellness Awards. Verifiable on the NMC public register.